Histogen Reports First Quarter 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 05/12/22
CORRECTING and REPLACING Paracrine Announces Appointment of Biotech Veteran David H. Crean, Ph.D.Business Wire • 05/12/22
Paracrine Announces Appointment of Biotech Veteran David Crean, Ph.D. to the Board of DirectorsBusiness Wire • 05/12/22
Histogen to Report First Quarter 2022 Financial Results and Provide Business UpdateGlobeNewsWire • 04/28/22
Histogen Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business UpdateGlobeNewsWire • 03/10/22
Histogen to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Business UpdateGlobeNewsWire • 03/03/22
Histogen and Amerimmune Announce the Presentation of Emricasan Data in COVID-19 at the American College of Allergy, Asthma, and Immunology ConferenceGlobeNewsWire • 11/02/21
Histogen to Present at the H.C. Wainwright 23rd Annual Global Investment ConferenceGlobeNewsWire • 08/31/21
Histogen and Amerimmune Announce Additional Findings from its Phase 1 Study of Emricasan in Mild Symptomatic COVID-19 PatientsGlobeNewsWire • 08/16/21